Log In
Print
BCIQ
Print
Print this Print this
 

Actimab-A

  Manage Alerts
Collapse Summary General Information
Company Actinium Pharmaceuticals Inc.
DescriptionActinium-225 attached to the anti-CD33 mAb lintuzumab (HuM195)
Molecular Target
Mechanism of Action 
Latest Stage of DevelopmentPhase I/II
IndicationAcute myelogenous leukemia (AML)
Partner

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today